By Rob Curran
Vera Therapeutics rose after the biotech firm said one of its product candidates showed promise in a mid-stage trial on patients with a kidney condition.
Shares of Vera Therapeutics rose 12% to $19.10 premarket.
The Brisbane, Calif., company said patients suffering from IgA nephropathy taking atacicept, including patients who switched over from placebo, showed improvement at the 72-week mark of a Phase 2b clinical trial.
“We believe these data further support our belief that atacicept has the disruptive potential to stand out as a disease-modifying treatment for patients with IgAN,” said Chief Executive Marshall Fordyce, in a statement.
Write to Rob Curran at [email protected]
Read the full article here
